RxDoctor Payments Data

Linda Desruisseau-Revis, APRN

Nurse Practitioner · Sarasota, FLNPI 1912459728

Payments from drug & device makers

$2,161in general payments, 2019–2025

Across 88 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$413
  • Biohaven Pharmaceutical Holding Company Ltd.$298
  • Novo Nordisk$253
  • Esperion Therapeutics, Inc.$193
  • Madrigal Pharmaceuticals$147
  • Amarin Pharma, Inc.$127
  • plus $730 from 14 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$2,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,161 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$84,406
Medicare patients
816
Services billed
1,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide30$26,710
ZenpepLipase/Protease/Amylase19$26,577
CreonLipase/Protease/Amylase22$24,778
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates209$12,812
ClenpiqSod Picosulf/Mag Ox/Citric Ac48$8,256
SutabSod Sulf/Pot Chloride/Mag Sulf42$6,794
Lubiprostone36$4,068
Omeprazole216$3,121
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl247$2,886
Pantoprazole Sodium209$2,862
Colestipol Hcl39$2,255
Budesonide DrBudesonide14$1,736
Famotidine113$1,190
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg44$702
Esomeprazole Magnesium14$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$413$51,48852 claims
Aimmune Therapeutics, Inc.Zenpep$125$26,57719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →